title: PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation.
abstract: OBJECTIVE
  Therapeutic decision-making in metastatic renal cell carcinoma (MRCC) is based on conventional radiological evaluation. Fluorodeoxyglucose positron emission tomography (FDG-PET) scans may modify this strategy.
  
  
  METHODS
  Patients with MRCC for whom a therapeutic decision had been made underwent an FDG-PET scan in order to complete the standard radiological evaluation.
  
  
  RESULTS
  Twenty-four patients and 26 FDG-PET scans were eligible. In 18 patients, metastatic disease was evaluable on the computed tomography (CT) scan; the FDG-PET scan was positive in 16 patients and negative in 10. In 2 patients, the FDG-PET scan was positive while they were considered disease free on radiological evaluation. In 5 patients (20.8%), the previous therapeutic decision was changed. Thirteen patients had a pathological evaluation for 19 sites. One patient out of 13 had a false-positive FDG-PET scan, while 4 sites out of 6 were false-negative. The sensitivity was 75% (95% CI: 47.6-92.7) and the predictive positive value was 92.3% (95% CI: 64-99.8). With a median follow-up of 24 months, 3 patients developed new metastatic sites.
  
  
  CONCLUSIONS
  Our data suggest that, when positive, an FDG-PET scan may modify the decision made; when negative, it should not modify decision-making especially for surgery, owing to its sensitivity.
authors.affiliation: Department of Medical Oncology and Radiotherapy, Hôpital Saint-André, University Hospital, CHU Bordeaux, France.
authors.forename: M S
authors.initials: MS
authors.lastname: Dilhuydy
authors.forename: A
authors.initials: A
authors.lastname: Durieux
authors.forename: A
authors.initials: A
authors.lastname: Pariente
authors.forename: H
authors.initials: H
authors.lastname: de Clermont
authors.forename: G
authors.initials: G
authors.lastname: Pasticier
authors.forename: J
authors.initials: J
authors.lastname: Monteil
authors.forename: A
authors.initials: A
authors.lastname: Ravaud
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy*; D003657:Decision Making; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18